Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00369434 · ClinicalTrials.gov registry record · Phase 3

Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women

A Phase 3 study of Menopause and Vasomotor System, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 3
Development phase
450
Enrollment target
20
Study locations

NCT00369434 is a Phase 3 study of Menopause and Vasomotor System that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 450 participants, below the 9,386-participant average among 54 other Menopause trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00369434, a Phase 3 study of Menopause and Vasomotor System, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
450 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) associated with menopause in a population of postmenopausal women.

Conditions Studied

Menopause Vasomotor System

Interventions

  • DRUG Desvenlafaxine succinate sustained-release (DVS SR)

Study Locations (20)

Florida

  • - Brooksville
  • - Inverness
  • - Miami
  • - New Port Richey
  • - Ocala
  • - St. Petersburg
  • - Tampa

Georgia

  • - Decatur
  • - Savannah

Idaho

  • - Boise
  • - Idaho Falls

Alabama

  • - Montgomery

Arizona

  • - Peoria

California

  • - Upland

Colorado

  • - Colorado Springs

Kansas

  • - Overland Park

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2006-06
Est. Completion 2007-02
Phase Phase 3

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

167 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00369434

The ClinicalTrials.gov registry entry for NCT00369434 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,386-participant average among 54 other Menopause trials with a reported enrollment target (95% lower). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Menopause appearing as the primary indexed condition, and to 1 intervention - of which Desvenlafaxine succinate sustained-release (DVS SR) is the first listed.

NCT00369434 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Georgia, Idaho.

Frequently Asked Questions

What is clinical trial NCT00369434 about?

NCT00369434 is a clinical study titled "Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women". The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) associated with menopause in a population of postmenopausal women.

What is the current status of trial NCT00369434?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2006-06. Estimated completion is 2007-02.

What conditions does trial NCT00369434 study?

This clinical trial studies the following conditions: Menopause, Vasomotor System.

What interventions are being tested in trial NCT00369434?

The interventions under investigation include: Desvenlafaxine succinate sustained-release (DVS SR) (DRUG).

Who is sponsoring clinical trial NCT00369434?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00369434 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Menopause

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Menopause

All registered trials for this condition

Vasomotor System

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.